Group 1 - The core viewpoint of the report is that Guoyuan International has given a "Buy" rating to CSPC Pharmaceutical Group (01093) with a target price of HKD 10.11, highlighting the company's active layout in innovative drug development and significant international achievements [1] - The company has built an international R&D team of over 2,000 people, focusing on oncology, psychiatry, and cardiovascular treatments, with R&D expenses of CNY 4.185 billion, a year-on-year increase of 7.9%, representing 27.1% of the revenue from traditional drugs [1][2] - The company has nearly 90 products in various stages of clinical trials, with 14 products submitted for market approval and over 30 in the registration clinical stage, laying a solid foundation for future revenue structure transformation [1] Group 2 - The innovative pipeline is accelerating, with licensing fee income of CNY 1.54 billion contributing to new growth, and cumulative potential milestone payments from overseas licensing agreements exceeding USD 15 billion [2] - Eight products, including SYS6091 (HER2ADC) and SYS6010 (EGFRADC), are in critical clinical stages, with expected data readouts and market applications between 2025 and 2027 [2] - SYS6010 (EGFRADC) has received three fast-track designations from the FDA and breakthrough therapy recognition from NMPA, with a potential market application expected in 2026 [2] Group 3 - For the first three quarters of 2025, the company's revenue was CNY 19.891 billion, a year-on-year decline of 12.3%, with a net profit of CNY 3.511 billion, down 7.06% [3] - The decline in revenue is primarily due to the impact of centralized procurement and price reductions in the medical insurance sector, with revenue from traditional drugs dropping to CNY 15.450 billion, a decrease of 17.2% [3] - In Q3, the company's revenue was CNY 6.62 billion, a year-on-year increase of 3.4% and a quarter-on-quarter increase of 5.7%, with a net profit of CNY 0.96 billion, up 27.2% [3]

Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093), highlighting improvements in the company's prescription drug business and strong growth in respiratory and cardiovascular sectors [1] Performance Summary - For the first three quarters of 2025, the company reported revenue of 19.891 billion yuan, a year-over-year decrease of 12.3%, and a net profit attributable to shareholders of 3.511 billion yuan, down 7.1% year-over-year. Adjusted net profit was 3.079 billion yuan, a decline of 23.0% year-over-year, aligning with CICC's expectations. In Q3 2025, revenue reached 6.618 billion yuan, showing a year-over-year increase of 3.4% and a quarter-over-quarter increase of 5.7%, indicating stabilization in performance. The prescription drug revenue in Q3 2025 was 5.202 billion yuan, with year-over-year growth of 1.6% and quarter-over-quarter growth of 9.6% [2] Business Segment Performance - In Q3 2025, revenue from various therapeutic areas included: - Neurological diseases: 1.914 billion yuan (YoY -4.2%) - Oncology: 594 million yuan (YoY -47.2%) - Anti-infection: 826 million yuan (YoY -8.6%) - Cardiovascular diseases: 474 million yuan (YoY +17.8%) - Respiratory diseases: 320 million yuan (YoY +72.7%) - Digestive system: 248 million yuan (YoY +13.7%) - Other areas: 362 million yuan (YoY +25.6%) - The company’s raw material drug revenue was 1.415 billion yuan, with a year-over-year increase of 10.5% and a quarter-over-quarter decrease of 6.4% [2] R&D Progress - The company is advancing its innovation-driven strategy, with significant progress in its small nucleic acid pipeline. Key projects include PCSK9, expected to enter Phase III by the end of 2025, and other clinical projects targeting chronic diseases such as blood lipid and blood pressure management. The company is also exploring targeted delivery for eye, lung, fat, and muscle diseases. Notable in-development products include anti-HER2 monoclonal antibodies and EGFR ADCs [3] Overseas Business Development - The company is enhancing its business development strategy and has established an international licensing platform. In the first three quarters of 2025, it achieved licensing revenue of 1.540 billion yuan. In Q3 2025, the company licensed SYH2086 (an oral small molecule GLP-1) to Madrigal Pharmaceuticals for global development and commercialization outside of China, which includes an upfront payment of 120 million USD and potential milestone payments of up to 1.955 billion USD, along with double-digit sales royalties. The company has additional innovative products in its pipeline that are expected to lead to further licensing opportunities and milestone revenue recognition [4] Profit Forecast and Valuation - Considering increased R&D investments, CICC has lowered its net profit forecasts for 2025 and 2026 by 12% and 15% to 4.760 billion yuan and 5.353 billion yuan, respectively. The current stock price corresponds to a price-to-earnings ratio of 17.1 times for 2025 and 15.0 times for 2026. The "outperform" rating is maintained, with a target price reduction of 15% to 11.00 HKD, reflecting a price-to-earnings ratio of 24.4 times and 21.4 times for 2025 and 2026, respectively, indicating a potential upside of 42.5% [5]